Remdesivir to Gain Authorization for Treatment in the UK

Remdesivir, an experimental antiviral drug manufactured by Gilead Sciences Inc., has recently been approved for treatment of COVID-19 in the UK for some patients. The UK has been struggling with the containment of the virus, currently holding the fifth most COVID-19 cases globally. Announcement of the drug approval was made on Tuesday (May 26th), following suit of other countries such as the United States and Japan who have also cleared the used of Remdesivir under "emergency authorization". These decisions were made following a NIH Clinical Trial showing that in advanced COVID-19 cases, Remdesivir was able to reduce hospital recovery-time by 31% compared to those given a placebo. Hospitals are currently operating on donated vials of the antiviral drug from the company, but are anticipated to run out some time in July. If COVID-19 case projections run its course, Gilead may see strong commercial revenues by the end of the year.

back

Remdesivir to Gain Authorization for Treatment in the UK

bullish
Remdesivir, an experimental antiviral drug manufactured by Gilead Sciences Inc., has recently been approved for treatment of COVID-19 in the UK for some patients. The UK has been struggling with the containment of the virus, currently holding the fifth most COVID-19 cases globally. Announcement of the drug approval was made on Tuesday (May 26th), following suit of other countries such as the United States and Japan who have also cleared the used of Remdesivir under "emergency authorization". These decisions were made following a NIH Clinical Trial showing that in advanced COVID-19 cases, Remdesivir was able to reduce hospital recovery-time by 31% compared to those given a placebo. Hospitals are currently operating on donated vials of the antiviral drug from the company, but are anticipated to run out some time in July. If COVID-19 case projections run its course, Gilead may see strong commercial revenues by the end of the year.
Comments

Write your comment....

Sign in to comment

read-time
1 min

85.00

Target Price

5/ 10

Confidence

1-2 Weeks

Timeframe
Share
catalyst icon
Earnings Release
catalyst icon
News
catalyst icon
SEC Filing
catalyst icon
Sentiment
catalyst icon
Other Catalyst

GILD Channel

Start new chat
aiodd-ad
next